SuppresSTEM research objectives include the development of novel antibody-based therapeutics, developed to modulate the Wnt pathway externally in combination with mitogenic receptor blockade. This will result in specific inhibition of cancer stem cells with minimal toxicity to healthy tissue. The likelihood of clinically translating these goals will be enhanced because testing will be performed on relevant human patient material (both tumor and normal) using organoid (patient tissue) technology and novel imaging readouts. In depth analysis of the phenotype of responsive organoids (patient material) will be used to identify a lead product. Successful execution of suppresSTEM will provide an innovative drug product and a drug screening tool ready for clinical validation that ultimately will increase the life expectancy and quality of cancer patients.